EQRXW
EQRx, Inc. [EQRXW] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
EQRXW Stock Summary
In the News
EQRXW Financial details
Company Rating
-
Market Cap
1.14B
Income
-83.79M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
216
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-11746.69
Forward P/E
-
PEG
2990.07
P/S
-
P/B
967.7
P/C
-
P/FCF
-3.44
Quick Ratio
18.43
Current Ratio
18.78
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.17
EPS next Y
-
EPS next Q
-
EPS this Y
-253.57%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
13.33%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-8%
ROE
-8%
ROC
-0.34%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0439-0.064
52W High
-
52W Low
-
RSI
-
Rel Volume
-
Avg Volume
-
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
Company Profile
- Market Capitalization 1.14B
- Employee 216
- CEO Mr. Alexis A. Borisy A.M.
- Headquarters Cambridge,MA,US
- IPO Date 2021-12-20
-
Website
https://www.eqrx.com 
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. Its product pipeline in development includes Aumolertinib, an EGFR inhibitor for the treatment of ?EGFR-mutated? non-small cell lung cancer (NSCLC); Sugemalimab, an anti-PD-L1 antibody for the treatment of ?stage III and IV ?NSCLC; Lerociclib, a CDK4/6 inhibitor to treat HR+/HER2- breast cancer; and EQ176, an anti-PD-1?antibody for the treatment of liver cancer. The company has partnerships with Exscientia and AbCellera Biologics Inc. EQRx, Inc. was founded in 2020 and is based in Cambridge, Massachusetts.
